Wag! Group (PET) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
14 Jan, 2026Executive summary
Q3 2024 revenue declined 39% year-over-year to $13.2M, with a net loss of $6.3M and an Adjusted EBITDA loss of $1.9M, driven by a challenging marketing environment and Google search changes.
Platform participants declined 41.9% year-over-year, impacting all revenue streams.
Significant non-recurring expenses of $0.9M affected Adjusted EBITDA; excluding these, the loss would have been $1M.
The company completed an $8.6M public offering in July 2024 to support liquidity.
Substantial doubt exists regarding the company's ability to continue as a going concern due to ongoing losses and liquidity constraints.
Financial highlights
Q3 2024 revenue: $13.2M (Wellness $6.5M, Services $5.4M, Pet Food & Treats $1.3M); net loss was $6.3M, and Adjusted EBITDA loss was $1.9M.
Net loss margin for Q3 2024 was (47.4)% versus (10.1)% in Q3 2023; Adjusted EBITDA margin was (14.7)% versus 4.6% last year.
Cash and cash equivalents were $8.4M as of September 30, 2024, down from $18.3M at year-end 2023.
Net cash used in operating activities for the nine months ended September 30, 2024 was $5.3M.
Cost of revenue (excluding D&A) was $1.1M, 9% of revenue; sales and marketing expense was $8.9M, 67% of revenue.
Outlook and guidance
Q4 2024 revenue guidance: $15M–$18M; Adjusted EBITDA: $(0.5)M to $0.5M.
Full year 2024 guidance: revenue $70M–$73M; Adjusted EBITDA: $(0.5)M to $0.5M.
October wellness revenue rebounded 79% month-over-month, with positive trends continuing into November.
Management expects operating losses to continue as investments in business growth persist.
The company is actively seeking to refinance its debt before the August 2025 maturity but cannot assure success.
Latest events from Wag! Group
- Record adjusted EBITDA and improved margins achieved, but liquidity and debt risks persist.PET
Q2 20242 Feb 2026 - Q4 rebounded with 17%+ sequential growth; 2025 revenue guided at $84–$88 million.PET
Q4 202426 Dec 2025 - Q1 2025 revenue fell 34.7%, net loss widened, and liquidity risks persist despite new partnerships.PET
Q1 202527 Nov 2025 - Chapter 11 filing, revenue drop, delisting, and asset sale mark a critical restructuring phase.PET
Q2 20257 Aug 2025